Efficacy of switching to risankizumab compared with continued adalimumab treatment in patients with moderate-to-severe plaque psoriasis - 22/08/19
Caitriona Ryan, MD, Charles Institute of Dermatology, University College, Dublin, Ireland; Jeffrey Crowley, MD, Bakersfield Dermatology and Skin Cancer Medical Group, Bakersfield, CA; Wendell Valdecantos, MD, AbbVie Inc, North Chicago, IL; Tianshuang Wu, PhD, AbbVie Inc, North Chicago, IL; Kristian Reich, MD, Dermatologikum Berlin and SCIderm Research Institute, Hamburg, Germany
Le texte complet de cet article est disponible en PDF. AbbVie Inc, participated in the study design; study research; collection, analysis, and interpretation of data; and writing, reviewing, and approving this abstract for submission. All authors had access to the data. |
Vol 81 - N° 4S1
P. AB55 - octobre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?